Publication | Open Access

Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

γ9δ2 TCancer ImmunosurveillanceInnacell γδ™Immune RegulationTumor ImmunityImmunologyImmune SurveillanceT Cell ImmunityImmunotherapeuticsCell BiologyCellular Immune ResponseImmunotherapyMedicineCell TransplantationPhase-i Study